Clinical Trial Update: Al18F-NOTA-octreotide PET Imaging in Neuroendocrine Tumors [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/3 trial investigating Al18F-NOTA-octreotide PET imaging for neuroendocrine tumors has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroendocrine Neoplasms
• Neuroendocrine Tumor

Snippet

Sponsor: Universitaire Ziekenhuizen KU Leuven | Conditions: Neuroendocrine Tumors | Phase 2, Phase 3 | Status: COMPLETED